» Articles » PMID: 10216504

TUM2-PK (pyruvate Kinase Type Tumor M2), CA19-9 and CEA in Patients with Benign, Malignant and Metastasizing Pancreatic Lesions

Overview
Journal Anticancer Res
Specialty Oncology
Date 1999 Apr 27
PMID 10216504
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The diagnostic value of the tumor marker pyruvate kinase type tumor M2 was evaluated in patients with benign, malignant and metastasizing pancreatic lesions and compared to the reference markers CA19-9 and CEA. This prospective study comprised 166 individuals; 66 patients had various pancreatic pathologies (38 histologically proven pancreatic cancer, 28 benign pancreatic lesions such as pseudotumorous pancreatitis, pseudocysts or pancreatic (cyst)adenoma) and 100 healthy blood donors served as controls. With a cut-off value of 28 U/ml (corresponding to a specificity of 90%) the sensitivity of TUM2-PK for pancreatic cancer (as related to the control group) was 79% (CA19-9: 65%, CEA: 22%). There was a good correlation between the TUM2-PK levels and tumor metastasis (p < 0.001 for no versus distant metastasis, p = n.s. for CA19-9 and CEA). However, TUM2-PK was also elevated in 64.3% of the patients with benign pancreatic pathologies. In our study TUM2-PK had good diagnostic qualities for pancreatic cancer and also showed better correlation to metastasis than CA 19-9 and CEA.

Citing Articles

An unusual pAIR: Anti-PKM2 antibody and occult pancreatic adenocarcinoma.

Spitz M, Anderson D, Vrabec T Am J Ophthalmol Case Rep. 2024; 36:102166.

PMID: 39351584 PMC: 11440255. DOI: 10.1016/j.ajoc.2024.102166.


Proteomic analysis of bovine mammary epithelial cells after in vitro incubation with S. agalactiae: potential biomarkers.

Tong J, Sun M, Zhang H, Yang D, Zhang Y, Xiong B Vet Res. 2020; 51(1):98.

PMID: 32746898 PMC: 7398202. DOI: 10.1186/s13567-020-00808-7.


Glycosylation in health and disease.

Reily C, Stewart T, Renfrow M, Novak J Nat Rev Nephrol. 2019; 15(6):346-366.

PMID: 30858582 PMC: 6590709. DOI: 10.1038/s41581-019-0129-4.


Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis.

Krishnan S, Whitwell H, Cuenco J, Gentry-Maharaj A, Menon U, Pereira S Int J Mol Sci. 2017; 18(12).

PMID: 29232830 PMC: 5751272. DOI: 10.3390/ijms18122670.


Alteration of cellular metabolism in cancer cells and its therapeutic prospects.

Biswal B, Das S, Das B, Rath R J Oral Maxillofac Pathol. 2017; 21(2):244-251.

PMID: 28932034 PMC: 5596675. DOI: 10.4103/jomfp.JOMFP_60_17.